One thing shareholders wantedAt least they're responding to shareholders. Littlejohn had lowest votes for last 2 years. No problem seeing the board shrink back to the size it was. There's a few others that had low vote totals too and it wouldn't surprise me that by year end 1 or 2 more move off. From my perspective the Board wasn't quite configured correctly to understand how they needed to lock in more capital for programs and were incorrect in assessing the riskiness of some of the investments done. Thankfully NASH ended up not really costing a whole lot of money as they were running that small 2a trial many years ago now.
Leaves some room for new blood that's can bring in some new skills. Still just about getting to cash flow positive, hitting that low end rev around $90 or a tad less, and getting the peptide to a place where proof of concept works, at a minimum, or we get to RECIST endpoints. I don't think the intial lower dose will see the most efficacy. To me, that lower one is more about reasserting the safety signals so the FDA and trial leaders are ok with it. It would be nice to see some efficacy "signals", but the dose may not be large enough for RECIST 30%+ shrinkage. I woudl expect some shrinkage, some stables and solid safety data. Then you move it up to the level they saw efficacy on before. So just as long as we see reasserted safety with the first batch and some positive signs around POC --that toxin's received well, getting in the right cells, stopping growth, etc... that's good in my book. Anything above that is super positive give it's a 220mg equivalent or something like that. Hope they at least tell us when the trial is live again, which should be soon.